March 2026
1. CERNIGLIARO F, Gallo C, Alessi G, Messina LM, et al
   Pediatric Migraine Aura Status and Cortical Laminar Necrosis: A Clinical Case and a Narrative Review.
   Rev Neurol. 2026;81:47684.
   

   >> Share

   
   
2. GINE-CIPRES E, Torres-Ferrus M, Gallardo VJ, Alpuente Ruiz A, et al
   Optimizing Chronic Migraine Care: The Impact of Advanced Practice Nurse Involvement in OnabotulinumtoxinA Administration.
   Rev Neurol. 2026;81:45618.
   

   >> Share

   
   February 2026
3. GARCIA-ESTEVEZ DA, Perez-Schofield BG, Sabbagh Casado NA
   [CefaleApp: A Mobile Application for Migraine Diagnosis in Primary Health Care].
   Rev Neurol. 2026;81:46506.
   

   >> Share

   
   January 2026
4. VALLADALES-RESTREPO LF, Diaz-Arteaga C, Navarrete-Santa LF, Santander-Pai MJ, et al
   Migraine and the Excessive Dispensation of Triptans: A Real-World Evidence Study of Colombian Patients.
   Rev Neurol. 2026;81:46355.
   

   >> Share

   
   December 2025
5. QUINTAS S, Sanchez NA, Gonzalez-Martinez A, Campos AV, et al
   [Influence of Clinical and Demographic Variables on the Characteristics of Migraine Attacks].
   Rev Neurol. 2025;80:44755.
   

   >> Share

   
   June 2025
6. PATINO DR, Zapata JC, Aguirre ALV
   Gepants: Key Features of A Potent Therapeutic Option and Considerations in The Latin American Context.
   Rev Neurol. 2025;80:38637.
   

   >> Share

   
   March 2025
7. POLANCO FERNANDEZ M, Gangas Barranquero L, Gonzalez-Quintanilla V, Madera Fernandez J, et al
   [Successful Management of Wearing-off effect with Eptinezumab: Lessons from a case with Chronic Migraine Refractory to Two Subcutaneous CGRP Antibodies].
   Rev Neurol. 2025;80:38974.
   

   >> Share

   
   November 2024
8. GARCIA-RON A, Arias-Vivas E, Bote-Gascon M, Gonzalez-Garcia N, et al
   [Usefulness of spontaneous drawing in the diagnostic guidance of pediatric patients with headache].
   Rev Neurol. 2024;79:265-271.
   

   >> Share

   
   
9. KLAIC-LOPEZ DA, Paez-Granda D, Romero-Carvajal F
   [Hemiplegic migraine: classic findings in a rare pathology].
   Rev Neurol. 2024;79:263-264.
   

   >> Share

   
   September 2024
10. SANCHEZ-RODRIGUEZ N, Millan-Vazquez M, Fernandez-Panadero A, Gomez-Caminero AE, et al
    [Management of migraine by hospital emergency departments: a retrospective observational study carried out at the Hospital Universitario Virgen del Rocio].
    Rev Neurol. 2024;79:155-160.
    

    >> Share

    
    May 2024
11. GARCIA-ESTEVEZ DA, Juanatey-Garcia A, Rodriguez-Garrido J, Sabbagh-Casado N, et al
    Reduction of plasma CGRP levels in migraine patients treated with erenumab or galcanezumab.
    Rev Neurol. 2024;78:293-294.
    

    >> Share

    
    January 2024
12. MINGUEZ-OLAONDO A, Lopez-Bravo A, Quintas S, Nieves-Castellanos C, et al
    [New therapeutic era for migraine attacks with recently approved monoclonal antibodies, ditans and gepants].
    Rev Neurol. 2024;78:47-57.
    

    >> Share

    
    October 2023
13. VINUEZA-BUITRON P, Montes-Pena VJ, Rodriguez-Mena D, Boada-Cuellar JL, et al
    [Habituation deficit study in patients with episodic migraine thru nociceptive blink reflex].
    Rev Neurol. 2023;77:159-165.
    

    >> Share

    
    June 2023
14. GUEVARA-MARTINEZ E, Arjona-Padillo A
    [Complete remission of a migraine after treatment with cisplatin].
    Rev Neurol. 2023;76:375.
    

    >> Share

    
    May 2023
15. PEREZ-RODRIGUEZ A, Bandres-Hernandez P, Anciones C, Terron-Cuadrado C, et al
    [Cardiovascular safety of new drugs for the acute and preventive treatment of migraine: gepants and ditans].
    Rev Neurol. 2023;76:295-308.
    

    >> Share

    
    April 2023
16. MADERA J, Rodriguez-Rodriguez EM, Gonzalez-Quintanilla V, Perez-Pereda S, et al
    [Peripheral stimulation of the trigeminal nerve by nasopharyngeal swabbing as a possible trigger of migraine attacks].
    Rev Neurol. 2023;76:227-233.
    

    >> Share

    
    March 2023
17. FRESAN-RESTITUTO D, Lacalle-Fabo E, Martin-Bujanda M, Sarobe-Carricas MT, et al
    Non-responder migraine patients to a first anti-CGRP monoclonal antibody benefit from a switch to a second one.
    Rev Neurol. 2023;76:213-216.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share